Moderna Shares Surge Over 85% on Cancer Vaccine Success

Moderna's shares surged sharply after positive results from a late-stage clinical trial of its mRNA-based cancer vaccine, developed in partnership with Merck. The company's stock gained more than 85% following the news. In the clinical study, the vaccine used in combination with Merck's immunotherapy drug Keytruda met the predefined primary goals. This outcome is considered a significant milestone in terms of treatment efficacy. Moderna's success once again highlights the potential of mRNA technology in cancer treatment. The company aims to replicate its earlier success with the COVID-19 vaccine in the oncology field. Market analysts note that this development strengthens Moderna's future growth prospects and solidifies its position in oncology. However, ongoing trial phases and regulatory approval processes remain key risk factors to monitor. This is not investment advice.

📊 MRNA — Piyasa Yorumu

▲ up · 60%

The headline indicates that the success in the cancer vaccine has given strong momentum to the stock. Although technical indicators show the RSI in neutral territory (46.6) and the MACD below the signal line, the price is slightly below the SMA20 and above the SMA50, pointing to potential for a short-term recovery. Despite the slight decline at the last close, positive news flow and the maintenance of support levels could support an upward move. However, caution is advised given the possibility that the news may already be priced in; therefore, the confidence level is kept moderate. A short-term upward trend is expected, but no excessive movement is anticipated.

RSI 14

46.6

MACD

0.25

24h Δ

-0.01%

Canlı Grafikler